EN
English✓简体中文繁體中文TürkçeEspañolBahasa MelayuBahasa IndonesiaTiếng ViệtPortuguêsРусский

Only complete language versions are shown.

Let’s talk

Choosing Gene Therapy: Check the Treatment, Approval, Risks, and Costs

EastMedGo

If someone recommends gene therapy to you, first ask them to write down the specific product or study name, the disease it is intended to treat, and the hospital and campus where it will be provided. Use this information to check the approval or research documents, then contact the hospital directly to confirm access and costs. Seeing “gene therapy,” “approved,” or a trial registration number is not enough to tell whether the arrangement is suitable for you.

Key points

  • Marketing approval in China applies to a specific product and indication. Overseas approval, patents, and trial registration cannot replace current Chinese approval and prescribing information.
  • The regulatory pathway must be confirmed for each program. It may involve a medicine, medical device, or new biomedical technology. Ask the hospital to explain the applicable pathway, current stage, and supporting basis. If the program’s status is unclear, do not pay or book travel that cannot be canceled or changed without loss.
  • Research registration is a starting point for checking information. The research team must confirm whether the specific center and cohort are open and whether you can enroll.
  • China’s applicable ethics rules prohibit charging research participants research-related fees. If you are unsure how a billed item is classified, first ask the research team and ethics committee for a written explanation.

What exactly does gene therapy change?

Different approaches may add a working gene to cells, regulate gene expression, or use tools to edit the cells’ existing DNA. Some deliver material directly into the body; others collect cells, modify and check them outside the body, then infuse them back. CAR-T is one type of genetically modified cell therapy; its process differs from treatments that deliver genes directly into the body. U.S. National Library of Medicine: How does gene therapy work?; Other genetic therapies.

Ask the doctor to explain, in relation to your diagnosis, which disease mechanism the treatment targets, what it changes or delivers, which cells it reaches, and which vector or delivery method it uses. Ask whether the expected benefit concerns symptoms, disease markers, or other outcomes, and how long the supporting evidence extends. For a genetic disease, bring the original genetic test report and ask whether the variant type matches the treatment. Cancer programs may require tumor marker results and a review of previous treatments. Even if the target variant is found, this does not necessarily mean the treatment is suitable: variant type, disease course, organ function, previous treatments, or antibodies against the vector may affect eligibility for a specific treatment. Ask the doctor to explain which tests are relevant to you.

First, ask for a written explanation of the arrangement

Ask the person introducing the program to provide the product’s generic name, brand name, and manufacturer or marketing authorization holder, or the study name, registration number, protocol number, sponsor, and the hospital, campus, and department conducting it. Then ask the hospital’s research or medical administration department: “Which regulatory pathway applies to this program, and is it currently research or clinical use? Which documents and official sources can I check?” If it involves a medicine, ask whether it will be used for an indication approved in China, used off-label, or used in research. If it involves a new biomedical technology, ask whether it has been filed as clinical research or approved for clinical translational use. For off-label use, ask the doctor to explain how it differs from the approved use, the supporting evidence, alternatives, and additional uncertainties. Ask the hospital to explain the consent process and costs.

Different pathways have different supporting requirements: filing a technology for clinical research is not the same as marketing approval for a medicine, and approval for clinical translational use is not the same as drug approval. Ask the hospital to provide documents, applicable conditions, and official lookup sources that match the specific technology or product, use, institution, and current stage, and to explain whether drug or medical device regulatory requirements apply. These documents still do not establish that the treatment is suitable for you personally. If you cannot confirm the details, check with the relevant authorities or a legal professional familiar with the field, and keep written responses. Do not classify the program yourself based only on its promotional name, product form, or ethics approval letter.

“Gene therapy” covers different methods, including direct delivery into the body and modification of cells outside the body followed by infusion. Ask the team to specify in writing the intended product, target tissue or cells, delivery method, manufacturer, and method of administration. “CRISPR” or “stem cells” alone is not enough to identify a specific program. Do not apply another product’s approval or effectiveness to this one simply because the technologies are similar.

How do you check a claim that a treatment is approved?

First ask the hospital whether this is a medicine, a medical device, or a technology approved for clinical translational use. For a medicine, request its Chinese approval number and current Chinese prescribing information. For a device, check its registration certificate, intended scope of use, and instructions. For clinical translational use of a new technology, ask the hospital to show approval documents matching the technology, use, and institution, and verify them with the responsible authority. These pathways cannot substitute for one another. You can try the National Medical Products Administration data search to check domestic or imported medicines; availability of the search service depends on the current page. Check the name, authorization holder, and number, and ask the hospital to identify the approval documents and current prescribing information. Give the doctor your diagnosis, genetic or other test results, age, previous treatments, and proposed method of administration, and compare them item by item with the indications and restrictions in the prescribing information. If the search finds nothing or the information differs, ask the hospital and authorization holder to help verify it with the drug regulator. Do not conclude on that basis alone that the product is approved or unapproved.

After confirming approval, also ask the actual hospital and pharmacy directly whether that campus can provide this specific product, whether it accepts patients from outside China, and how to arrange an assessment. Drug approval does not mean the hospital has the product or that you meet the conditions for use.

What should you check after finding a trial registration number?

For drug trials, start with the Drug Clinical Trial Registration and Information Disclosure Platform. For other research leads, check the Chinese Clinical Trial Registry or ClinicalTrials.gov. On the drug trial platform, use the “Trial Disclosure and Search” section. The National Medical Research Registration and Filing Information System provides access to medical research registration and online services for new biomedical technologies. Ask the institution conducting the program to explain which platform applies and provide registration, filing, or public disclosure information that you can verify. Platforms differ in what they include and what the public can see. If you cannot find a record, ask the program team where it is registered and which regulatory pathway applies; do not decide for yourself that it is legal or illegal.

Open the record and save the search date, study title, registration number, protocol number, sponsor, study phase, intervention, inclusion and exclusion criteria, hospital, cohort, recruitment status, and contact details. Compare these with the information supplied by the person introducing the program, especially whether the hospital and product match. Registration provides research information only; it does not prove marketing approval, effectiveness, safety, or your eligibility. An overall status of “recruiting” also does not guarantee that the target campus and cohort still have places.

Use contact details from the registration record or the hospital’s official website to ask the research team directly: “Is [cohort] for [registration number] at [hospital and campus] currently screening patients? Do you accept patients from outside China? Which medical records are needed, and who is responsible for replying?” If the program is described as investigator-initiated, the team must still explain who is responsible for it, the applicable review procedures, and the participating centers. Research conducted by a hospital must not be presented as a marketed product. An appointment, prescreening, or signing a consent form does not guarantee enrollment. While waiting, ask your usual treating doctor and the research doctor to discuss timing; do not stop medication on your own.

What should the research doctor explain before you sign?

Request an informed consent form you can understand. If language is a barrier, ask for appropriate interpretation or translation. Ask the research doctor to explain, in relation to your condition, the study’s purpose, possible group assignments, evidence of benefit, possible risks and unknowns, alternative care, and the frequency of tests and visits. For a genetic disease, ask the doctor to refer to your original genetic test report when explaining the variants or disease mechanisms targeted by the study. Having a target variant does not mean you meet all inclusion and exclusion criteria.

Specific risks depend on the product, pretreatment, and your circumstances. Ask the team whether pretreatment or immune suppression is needed, and about possible infusion or immune reactions, infections, low blood cell counts, and organ damage. Some products may involve risks from gene insertion, clonal expansion, and related cancers. Gene editing may also cause off-target changes or unintended changes at the target site. Benefits may weaken over time. These effects do not occur with every product, but you should ask which risks are known and unknown for the specific treatment. U.S. FDA: Guidance on gene editing products.

Ask about the specific product’s vector or delivery system, whether vector shedding may occur and what precautions are needed, reproductive precautions, and which new symptoms must be reported immediately. If cell collection, manufacturing, and release for use are involved, ask what happens if collection or manufacturing fails. Do not assume that successful collection guarantees that treatment can be given.

Confirm who will manage acute problems, what needs to be monitored, how often follow-up is required, who will contact you about abnormal findings, and who pays. Even a single dose may require long-term observation. Follow-up procedures and duration depend on the specific product and protocol; ask how care will continue if the center or sponsor can no longer provide it. FDA guidance on long-term follow-up. Ask how to apply for free treatment, compensation, or damages for research-related harm, and record the contact details of the research doctor and ethics committee. Participants may decide to withdraw from research without needing a doctor’s permission. At the same time, discuss safe discontinuation, further treatment and follow-up, and the handling of already collected samples and data with the team as early as possible. Stopping treatment and withdrawing from all follow-up may be separate decisions. Ask the team to explain the consequences of each, and obtain a copy of the signed consent form.

For blood, tissue, cells, and genetic data, ask why they are collected, how long they will be stored, who will use or receive them, arrangements for cross-border transfer, whether future research requires separate consent, whether you can obtain the raw data, how incidental findings will be communicated, whether research results need clinical confirmation, and what happens after you withdraw consent. Ask the hospital to confirm the specific cross-border rules for samples and data based on the actual status of those involved, the source, and the intended use.

What should you check in a quote or a claim that a trial is free?

Ask the hospital or research team for an itemized written list covering screening, genetic testing, the product or study medicine, collection and manufacturing, administration, hospital stays, management of complications, follow-up, interpretation, transportation, and accommodation. Ask the hospital or research team to specify each item’s purpose, amount or whether an estimate is pending, who pays, the organization receiving payment, payment timing, and refund conditions. Also ask which costs will already have been incurred if screening is unsuccessful, manufacturing fails, treatment is canceled, or the hospital stay is extended. Do not pay an individual’s account for program charges you cannot verify. Confirm the payment recipient through the hospital’s official channels and obtain receipts.

In China, Article 17 of the ethical review measures states that, for research within their scope, participants must not be charged research-related fees and must receive appropriate compensation for reasonable expenses incurred because of the research. Drug trial sponsors and trial institutions must not charge participants trial-related fees. There are also explicit requirements for sponsors to cover study medicines and related medical tests. Article 8 of the Regulations for Implementation of the Drug Administration Law; Article 45 of Good Clinical Practice for Drug Trials.

For programs subject to the Regulations on the Administration of Clinical Research and Clinical Translational Use of New Biomedical Technologies, Article 20 prohibits research-initiating institutions and research institutions from charging participants fees related to clinical research. Article 34 states that, for technologies approved for clinical translational use, eligible medical institutions may charge for clinical use in accordance with the rules. Clinical trials conducted to develop medicines or medical devices follow the corresponding laws and regulations. Ask the hospital to explain which pathway applies to this program first; do not decide which provision applies based only on the term “gene therapy.” Full regulations

Whether specific items—such as screening, routine care, post-trial care, transportation, accommodation, or agency services—count as research-related costs or qualify for compensation cannot be determined by their names alone. Ask the team to state in writing the basis for each item and who is responsible for paying. Inclusion in an estimate does not make it permissible to charge research-related fees prohibited by law. If there is a dispute, ask the ethics committee or relevant authority to explain. You must also confirm coverage with your insurer; an estimate is not a promise of insurance coverage.

If someone charges a “trial place reservation fee” or refuses to explain charges for study medicines or tests, pause payment. Independently contact the hospital’s research office and ethics committee, provide the program number and quote, and request written verification. If a dispute remains, consult the local health authority or drug regulator. Keep quotes, receipts, and communication records.

What should be confirmed before you travel and return home?

Before departure, ask the center to confirm in writing the type of assessment, hospital campus, how to submit records, visa or medical appointment arrangements, expected length of stay, caregiver requirements, and next steps if you do not pass screening or treatment is delayed. Submit original medical records, pathology or genetic reports, and previous treatment records through a secure channel designated by the hospital. First ask whether original documents or repeat testing are required.

Before treatment is given, ask the team to write down the warning symptoms that apply to the treatment and a 24-hour contact number. If severe or rapidly worsening symptoms occur, such as difficulty breathing or changes in consciousness, alert medical staff immediately if you are in the hospital. Outside the hospital, seek emergency care where you are, then contact the research or treatment team. Do not wait to confirm whether the symptoms are related to treatment.

Before returning home, ask the treatment team to confirm emergency care arrangements, whether you can travel, and whether a doctor at your destination has agreed to take over your care. Take the product or study name, administration date, main medicines used, complications, test results, follow-up visit plan, and contact details. Record which tests can be done locally, who will review the results, and who will contact you about abnormal findings. Keep any arrangements that are not yet settled marked as awaiting confirmation.

Frequently asked questions

Is a product approved overseas also approved in China?

Overseas approval does not establish approval in China. Check current Chinese approval and prescribing information using the product name and authorization holder, and ask the hospital to confirm actual availability.

Does a number on a registration page prove that the study is approved?

No. Registration is separate from regulatory or ethics review. Ask the research team to explain the applicable pathway, and verify the participating center and ethics review status through the hospital.

Can I trust a claim of “a permanent cure with one dose”?

Ask the doctor to explain the clinical evidence for that specific product, how long benefits last, and what remains unknown. Do not treat a promotional guarantee as your personal outcome. Even a single dose may require long-term follow-up.

Can I pay if the only document shown is an ethics approval letter?

First verify the study, protocol version, center, and cost arrangements covered by the letter. Ethics review is not marketing approval. If you have questions about research-related charges, contact the hospital’s research office or ethics committee first.

If I cannot find the research registration, does that definitely mean something is wrong?

You cannot conclude this from a single search. Ask the program team for the full study name, registration platform, and number, and independently verify these with the hospital conducting the study. If key details about the program’s identity or supporting basis remain unclear, pause payment and travel.

What if someone suggests editing embryos or guarantees improved abilities in the next generation?

Pause and consult an independent specialist service and ethics body with the relevant qualifications. WHO has issued clear warnings about clinical use of heritable human germline genome editing. Do not confuse genetic testing with embryo gene editing. WHO information

Can I use this guide to check a CAR-T program too?

You can start by checking the product, research status, and basis for charges. To confirm specific arrangements for cell collection, manufacturing, bridging treatment, infusion, and monitoring with the team, also refer to the CAR-T treatment process and long-term follow-up guides.

Sources

Information checked: November 6, 2026. Details of specific products, studies, and hospital arrangements should be checked again when making a decision.

Chat on WhatsAppEmail